DE60319719D1 - Verfahren zur voraussage der erhöhung von cholesterin während einer immunosuppresiven therapie - Google Patents

Verfahren zur voraussage der erhöhung von cholesterin während einer immunosuppresiven therapie

Info

Publication number
DE60319719D1
DE60319719D1 DE60319719T DE60319719T DE60319719D1 DE 60319719 D1 DE60319719 D1 DE 60319719D1 DE 60319719 T DE60319719 T DE 60319719T DE 60319719 T DE60319719 T DE 60319719T DE 60319719 D1 DE60319719 D1 DE 60319719D1
Authority
DE
Germany
Prior art keywords
presentation
increase
cholesterol during
immunosuppresive therapy
immunosuppresive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60319719T
Other languages
English (en)
Other versions
DE60319719T2 (de
Inventor
Sridhar Kudaravalli
Mihael Hristos Polymeropoulos
Rosarelis Torres
Curt Douglas Wolfgang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32043422&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60319719(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of DE60319719D1 publication Critical patent/DE60319719D1/de
Publication of DE60319719T2 publication Critical patent/DE60319719T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE60319719T 2002-09-30 2003-09-29 Verfahren zur voraussage der erhöhung von cholesterin während einer immunosuppresiven therapie Expired - Lifetime DE60319719T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41512302P 2002-09-30 2002-09-30
US415123P 2002-09-30
PCT/EP2003/010798 WO2004029618A2 (en) 2002-09-30 2003-09-29 Methods to predict cholesterol elevations during immunosuppressant therapy

Publications (2)

Publication Number Publication Date
DE60319719D1 true DE60319719D1 (de) 2008-04-24
DE60319719T2 DE60319719T2 (de) 2009-03-12

Family

ID=32043422

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60319719T Expired - Lifetime DE60319719T2 (de) 2002-09-30 2003-09-29 Verfahren zur voraussage der erhöhung von cholesterin während einer immunosuppresiven therapie

Country Status (14)

Country Link
US (2) US7732134B2 (de)
EP (1) EP1549770B1 (de)
JP (1) JP4575775B2 (de)
CN (1) CN100453650C (de)
AT (1) ATE389034T1 (de)
AU (1) AU2003287955B2 (de)
BR (1) BR0314552A (de)
CA (1) CA2500979A1 (de)
DE (1) DE60319719T2 (de)
ES (1) ES2302959T3 (de)
HK (1) HK1084445A1 (de)
IL (1) IL167639A (de)
PT (1) PT1549770E (de)
WO (1) WO2004029618A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006128660A1 (en) * 2005-05-31 2006-12-07 Novartis Ag Combination of hmg-coa reductase inhibitors amd mtor inhibitors
PL2496720T3 (pl) 2009-11-06 2021-01-11 The Board Of Trustees Of The Leland Stanford Junior University Nieinwazyjna diagnoza odrzucenia przeszczepu u pacjentów z przeszczepem narządu
KR101924162B1 (ko) * 2010-03-15 2018-11-30 버지니아 커먼웰스 유니버시티 기도의 염증 및 이상성 점액섬모 전달의 치료법으로서의 에어로졸화 댑손
US20130203769A1 (en) * 2012-02-08 2013-08-08 University Of Cincinnati Targeting Metabolic Adaptive Responses to Chemotherapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686246A (en) 1995-08-03 1997-11-11 Kornman; Kenneth S. Detecting genetic predisposition to periodontal disease
US5698399A (en) * 1996-04-05 1997-12-16 Duff; Gordon W. Detecting genetic predisposition for osteoporosis
US6210877B1 (en) * 1997-03-10 2001-04-03 Interleukin Genetics, Inc. Prediction of coronary artery disease
US6524795B1 (en) 1997-03-10 2003-02-25 Interleukin Genetics, Inc. Diagnostics for cardiovascular disorders
GB9711040D0 (en) * 1997-05-29 1997-07-23 Duff Gordon W Prediction of inflammatory disease
CN1753903B (zh) * 2001-11-19 2010-05-12 白介素遗传公司 影响转录和对炎性和传染性疾病的敏感性的白细胞介素-1基因座的功能多态性

Also Published As

Publication number Publication date
CA2500979A1 (en) 2004-04-08
EP1549770B1 (de) 2008-03-12
US20100184798A1 (en) 2010-07-22
DE60319719T2 (de) 2009-03-12
US20060246439A1 (en) 2006-11-02
JP2006500930A (ja) 2006-01-12
AU2003287955B2 (en) 2007-06-21
IL167639A (en) 2011-10-31
AU2003287955A1 (en) 2004-04-19
ATE389034T1 (de) 2008-03-15
BR0314552A (pt) 2005-08-09
WO2004029618A2 (en) 2004-04-08
PT1549770E (pt) 2008-06-24
EP1549770A2 (de) 2005-07-06
HK1084445A1 (en) 2006-07-28
ES2302959T3 (es) 2008-08-01
JP4575775B2 (ja) 2010-11-04
CN100453650C (zh) 2009-01-21
WO2004029618A3 (en) 2004-06-17
CN1685062A (zh) 2005-10-19
US7732134B2 (en) 2010-06-08
AU2003287955B9 (en) 2004-04-19

Similar Documents

Publication Publication Date Title
ATE411018T1 (de) Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en)
ATE526041T1 (de) Verfahren zur hemmung okularer vorgänge
SG155054A1 (en) Human anti- neutralizing antibodies as selective pathway inhibitors
MY151032A (en) Treatment of tnf? related disorders
DE60312309D1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
HUP0303917A2 (hu) Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére
MX349188B (es) Sns - 595 y metodos para utilizar el mismo.
DK1429756T3 (da) Behandling af xanthoma med azetidinonderivater som sterolabsorptionsinhibitorer
DE602004017283D1 (de) Verfahren zur behandlung von schwerer herzinsuffizienz und medikament dafür
TW200507840A (en) Method of treating multiple myeloma
HK1099525A1 (en) Methods of treating atherosclerosis
IS5101A (is) Aðferðir við inngjöf efnasambanda sem eru mótefnigegn CD40L í sambandi við læknismeðferð
PT1529116E (pt) Métodos para o tratamento da demência com base no genótipo da apo e
DE60319719D1 (de) Verfahren zur voraussage der erhöhung von cholesterin während einer immunosuppresiven therapie
DE60144493D1 (de) Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen
MXPA04010927A (es) Metodos y composiciones para el tratamiento de enfermedades y trastornos inflamatorios/autoinmunes producidos por linfocitos t en sujetos que padecen una deficiencia en la regulacion de glucocorticoides.
BRPI0507404A (pt) método de tratamento de um indivìduo que tem psorìase e kit
DE60237112D1 (de) Verfahren zum behandeln von leder
ATE546548T1 (de) Verfahren zur prognose des nutzens einer antioxidationshemmenden therapie zur vorbeugung von herz-kreislauf-erkrankungen bei hyperglykämischen patienten
ATE478942T1 (de) Verfahren zur verwendung regenerativer zellen bei der behandlung von nierenkrankheiten und störungen
ATE384266T1 (de) Verfahren zur prognose des kumulativen überlebens von patienten
CY1116323T1 (el) ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ TNFα-ΣΧΕΤΙΖΟΜΕΝΩΝ ΔΙΑΤΑΡΑΧΩΝ
ATE297745T1 (de) Chemische modifizierung von harn von säugern

Legal Events

Date Code Title Description
8363 Opposition against the patent
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN